Your browser doesn't support javascript.
loading
Seladelpar: New hope for patients with primary biliary cholangitis.
Nevzorova, Yulia A; Cubero, Francisco Javier.
Affiliation
  • Nevzorova YA; Department of Immunology, Ophthalmology and ENT, Complutense University School of Medicine, Madrid, Spain; Health Research Institute Gregorio Marañón (IiSGM), Madrid, Spain; Centre for Biomedical Research, Network on Liver and Digestive Diseases (CIBEREHD), Madrid, Spain.
  • Cubero FJ; Department of Immunology, Ophthalmology and ENT, Complutense University School of Medicine, Madrid, Spain; Health Research Institute Gregorio Marañón (IiSGM), Madrid, Spain; Centre for Biomedical Research, Network on Liver and Digestive Diseases (CIBEREHD), Madrid, Spain. Electronic address: fcubero@ucm.es.
Med ; 5(5): 377-379, 2024 May 10.
Article in En | MEDLINE | ID: mdl-38733969
ABSTRACT
The study by Hirschfield et al.1 demonstrated safety profile and clinically significant effectiveness of the peroxisome proliferator-activated receptor delta (PPARδ) agonist seladelpar in patients with primary biliary cholangitis, highlighting its plausible use as a second-line treatment to reduce disease activity and pruritus.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pruritus / Liver Cirrhosis, Biliary Limits: Humans Language: En Journal: Med Year: 2024 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pruritus / Liver Cirrhosis, Biliary Limits: Humans Language: En Journal: Med Year: 2024 Document type: Article Affiliation country: Country of publication: